CCS gathered insights from more than 1,500 individuals living with diabetes regarding challenges they face when it comes to managing their chronic disease

• 57% think GLP-1 weight loss drugs alone may be a silver bullet for their health
• 71% believe any organization that touches their diabetes care should be engaging with them in between doctor visits
• 42% reported experiencing a life-threatening emergency caused by their diabetes
• 41% stated that they typically see their clinician only 2–3 times a year to manage their diabetes

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced a new report revealing 57% of individuals living with diabetes in the United States think GLP-1 weight loss drugs alone may be a silver bullet for helping achieve their health goals. CCS, in collaboration with independent market research firm PureSpectrum, surveyed more than 1,500 individuals living with diabetes to understand their attitude as it relates to an array of timely issues, including growing demand for GLP-1 weight loss drugs and whether people living with type 2 diabetes feel like their provider relationship is setting them up for success when it comes to self-management of their chronic disease.

“GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health and well-being of those living with diabetes,” said Dr. Arti Masturzo, Chief Medical Officer at CCS. “These drugs do offer hope for those living with diabetes and others looking to manage obesity, but they should be prescribed in conjunction with hands-on personalized education and coaching, as well as the appropriate medical device technology needed to streamline diabetes self-management.”

Beyond GLP-1 weight loss drugs, a broad lack of focus on patient education and coaching for people living with diabetes was also highlighted in this report. Approximately one-third (36%) of respondents felt they did not have enough information provided when they were first diagnosed with their condition — or were first responsible for their own care — to help them effectively manage their condition.

Many of these same respondents stressed the value of additional clinical touchpoints to manage their diabetes. In fact, nearly three-quarters (71%) believe any organization that supports their diabetes care management should also be engaging with them in between doctor visits. Still, 41% of those surveyed stated that they typically see their clinician only two to three times a year to manage their diabetes, suggesting there remains a significant gap in support to help people stay healthy.

At times, infrequent patient engagement and a lack of proper education and coaching can contribute to patients with diabetes facing dangerous and costly health issues. According to the CCS report, 42% reported experiencing a life-threatening emergency caused by their diabetes. Of that group, 82% also said that the emergency could have been prevented with better support in the management of their diabetes.

Finally, a majority of respondents of this survey (94%) stated they’d be likely to consistently engage with their diabetes medical supplier as a critical part of their care team. To fill this patient engagement gap, traditional medical suppliers — like CCS — have transitioned to provide more holistic chronic care management technology and services.

To review the full report from CCS, please visit: https://ccsmed.com/consumerinsights. CCS conducted this survey in December 2023 in collaboration with independent market research firm PureSpectrum using its platform to engage 1,504 people in the U.S. living with any form of diabetes and who have been prescribed a continuous glucose monitor (CGM). For more information on PureSpectrum’s methodology, visit www.PureSpectrum.com.

About CCS

CCS is a leading chronic care management company, providing clinical solutions and home-delivered medical supplies for those living with chronic conditions, particularly diabetes. The company works specifically with health plans, providers, and employers to defragment the patient journey by combining all of the following into one seamless platform experience: medical devices, pharmaceuticals and clinical education, and coaching services. To holistically support individuals living with diabetes, CCS has advanced its AI-based machine learning and large language models to support the identification and timely engagement of high-risk members before serious adherence issues arise. CCS supports 180,000+ people living in the United States and delivers more than 1.2 million orders directly to their homes each year. After serving individuals for 30 years, CCS has the relationships, experience, and data in place to create a new era of home-based, proactive chronic care management. To learn more about CCS, please visit CCSMed.com; LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240307559304/en/

“GLP-1 weight loss drugs alone are not a silver bullet when it comes to improving the health and well-being of those living with diabetes...” - Dr. Arti Masturzo, CMO at CCS